Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance, pharmacokinetics, and metabolism study of DC-806 in healthy male volunteers
NL-OMON60409Phase 1Completed
- Sponsor
- DICE Therapeutics
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of navepdekinra, sponsored by DICE Therapeutics. Primary endpoints: Urinary excretion and recovery of total radioactivity and DC-806, Fecal and total excretion and recovery of total radioactivity and DC-806 and 3 more. Started Aug 2023; status: completed.
02
Drugs
navepdekinra
Beyond the preview
Go deeper on NL-OMON60409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60409.